The FDA and drug safety: a proposal for sweeping changes

Area of Science:

• Pharmacovigilance
• Regulatory Science
• Public Health Policy

Background:

• Current Food and Drug Administration (FDA) drug safety regulation faces significant challenges.
• Limitations include undetected adverse events in preapproval studies and underreporting in postmarketing surveillance.
• Manufacturer non-compliance with postmarketing safety studies and perceived industry influence further weaken the system.

Purpose of the Study:

• To identify critical deficiencies in the current FDA drug safety regulatory framework.
• To propose actionable recommendations for improving FDA's drug safety oversight and public trust.
• To advocate for legislative changes to enhance FDA's authority and resources.

Main Methods:

• Analysis of existing FDA regulatory processes and identified systemic weaknesses.
• Review of postmarketing surveillance data and manufacturer compliance issues.
• Formulation of policy recommendations based on identified problems.

Main Results:

• Significant underreporting of adverse events hinders accurate risk assessment.
• FDA lacks sufficient authority to enforce compliance with postmarketing safety commitments.
• The agency's structure, resources, and expertise are insufficient for optimal drug safety monitoring.

Conclusions:

• The FDA's drug safety system requires substantial changes to ensure public health.
• Congressional action is needed to grant FDA greater enforcement power and resources.
• Reorganization and improved advisory committee composition are crucial for strengthening drug safety evaluation and monitoring.